State Board of Administration of Florida Retirement System raised its position in Qiagen NV (NYSE:QGEN) by 0.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 300,592 shares of the company’s stock after purchasing an additional 470 shares during the quarter. State Board of Administration of Florida Retirement System owned 0.13% of Qiagen worth $10,355,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc grew its stake in shares of Qiagen by 2.0% during the third quarter. Vanguard Group Inc now owns 6,627,163 shares of the company’s stock worth $251,037,000 after purchasing an additional 128,125 shares in the last quarter. Frontier Capital Management Co. LLC grew its stake in shares of Qiagen by 1.3% during the fourth quarter. Frontier Capital Management Co. LLC now owns 2,653,307 shares of the company’s stock worth $91,406,000 after purchasing an additional 34,078 shares in the last quarter. Morgan Stanley grew its stake in shares of Qiagen by 16.3% during the third quarter. Morgan Stanley now owns 1,468,052 shares of the company’s stock worth $55,611,000 after purchasing an additional 205,698 shares in the last quarter. Bank of Montreal Can grew its stake in shares of Qiagen by 9.2% during the fourth quarter. Bank of Montreal Can now owns 890,316 shares of the company’s stock worth $30,672,000 after purchasing an additional 74,791 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Qiagen by 3.0% during the fourth quarter. Rhumbline Advisers now owns 190,464 shares of the company’s stock worth $6,561,000 after purchasing an additional 5,570 shares in the last quarter. 62.35% of the stock is currently owned by institutional investors.
NYSE QGEN opened at $36.68 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.22 and a quick ratio of 2.05. Qiagen NV has a 1 year low of $31.10 and a 1 year high of $39.45. The firm has a market capitalization of $8.37 billion, a price-to-earnings ratio of 27.37, a P/E/G ratio of 2.27 and a beta of 0.89.
A number of equities analysts recently commented on the stock. BidaskClub upgraded shares of Qiagen from a “sell” rating to a “hold” rating in a research note on Friday, November 2nd. Morgan Stanley boosted their target price on shares of Qiagen from $39.00 to $41.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 31st. Jefferies Financial Group reiterated a “neutral” rating on shares of Qiagen in a research note on Monday, January 21st. Zacks Investment Research reiterated a “hold” rating on shares of Qiagen in a research note on Wednesday, November 14th. Finally, Commerzbank reiterated a “buy” rating on shares of Qiagen in a research note on Tuesday, October 30th. Seven research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $41.00.
COPYRIGHT VIOLATION WARNING: This story was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/4146200/qiagen-nv-qgen-shares-bought-by-state-board-of-administration-of-florida-retirement-system.html.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Read More: Options Trading – What is a Straddle?
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NYSE:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.